Processa Pharmaceuticals, Inc. Lessee, Operating Lease, Liability, to be Paid, Year One
Processa Pharmaceuticals, Inc. (PCSA) had Lessee, Operating Lease, Liability, to be Paid, Year One of $70.04 thousand as of 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2025-03-20
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $70.04K.
- 2024-09-30: Lessee, Operating Lease, Liability, to be Paid, Year One $70.04K.
- 2024-06-30: Lessee, Operating Lease, Liability, to be Paid, Year One $70.04K.
- 2024-03-31: Lessee, Operating Lease, Liability, to be Paid, Year One $70.04K.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2024-12-31 | $70.04K 10-K · filed 2025-03-20 |
| 2024-09-30 | $70.04K 10-Q · filed 2024-10-30 |
| 2024-06-30 | $70.04K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $70.04K 10-Q · filed 2024-05-10 |
| 2023-12-31 | $92.39K 10-K · filed 2024-03-29 |
| 2023-09-30 | $92.36K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $92.36K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $92.36K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $93.84K 10-K · filed 2023-03-30 |
| 2022-09-30 | $93.63K 10-Q · filed 2022-11-08 |
| 2022-06-30 | $6.42K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $6.42K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $75.97K 10-K · filed 2022-03-30 |
| 2021-09-30 | $75.97K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $75.97K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $75.97K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $96.72K 10-K · filed 2021-03-25 |
| 2020-09-30 | $90.50K 10-Q · filed 2020-11-12 |
| 2020-06-30 | $90.50K 10-Q · filed 2020-08-05 |
| 2020-03-31 | $90.50K 10-Q · filed 2020-05-15 |
| 2019-12-31 | $92.60K 10-K · filed 2020-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |